# New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

> **NCT07559760** · PHASE2 · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab

## Key facts

- **NCT ID:** NCT07559760
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559760, "New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07559760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*